China Cord Blood Corp. (NYSE:CO) shares fell 2% on Wednesday . The company traded as low as $5.29 and last traded at $5.32, with a volume of 71,589 shares trading hands. The stock had previously closed at $5.43.

A number of research firms recently weighed in on CO. Zacks Investment Research downgraded shares of China Cord Blood Corp. from a “hold” rating to a “sell” rating in a research report on Monday, August 29th. TheStreet downgraded shares of China Cord Blood Corp. from a “buy” rating to a “hold” rating in a research report on Thursday, August 4th. One analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $6.75.

The firm’s 50-day moving average price is $5.25 and its 200-day moving average price is $5.77. The firm has a market capitalization of $388.38 million, a price-to-earnings ratio of 27.85 and a beta of 0.56.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/china-cord-blood-corp-co-trading-down-2.html

China Cord Blood Corp. (NYSE:CO) last posted its earnings results on Monday, August 22nd. The company reported $0.03 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.03. China Cord Blood Corp. had a net margin of 13.90% and a return on equity of 5.85%. The firm had revenue of $26 million for the quarter, compared to analyst estimates of $26.23 million. On average, analysts forecast that China Cord Blood Corp. will post $0.15 EPS for the current year.

A number of large investors have recently bought and sold shares of CO. GLG Partners LP increased its position in shares of China Cord Blood Corp. by 2.2% in the second quarter. GLG Partners LP now owns 923,931 shares of the company’s stock worth $5,313,000 after buying an additional 19,800 shares during the period. Panagora Asset Management Inc. increased its position in shares of China Cord Blood Corp. by 5.2% in the second quarter. Panagora Asset Management Inc. now owns 186,430 shares of the company’s stock worth $1,072,000 after buying an additional 9,187 shares during the period. State Street Corp increased its position in shares of China Cord Blood Corp. by 2.7% in the second quarter. State Street Corp now owns 28,995 shares of the company’s stock worth $167,000 after buying an additional 762 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of China Cord Blood Corp. by 8.9% in the first quarter. Renaissance Technologies LLC now owns 721,900 shares of the company’s stock worth $4,382,000 after buying an additional 59,045 shares during the period. 9.35% of the stock is currently owned by hedge funds and other institutional investors.

China Cord Blood Corp. Company Profile

China Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee.

5 Day Chart for NYSE:CO

Receive News & Ratings for China Cord Blood Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Cord Blood Corp. and related companies with MarketBeat.com's FREE daily email newsletter.